Related Experiment Video

Updated: Dec 24, 2025

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.6K

Vital Signs: Newly Reported Acute and Chronic Hepatitis C Cases - United States, 2009-2018

A Blythe Ryerson1, Sarah Schillie1, Laurie K Barker1

  • 1Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC.

MMWR. Morbidity and Mortality Weekly Report
|April 10, 2020
PubMed

Insights

Hepatitis C cases are rising, especially among young adults. Increased testing and early diagnosis are crucial for preventing chronic infection and liver disease, as many infected individuals remain unaware of their condition.

Area of Science:

  • Public Health
  • Infectious Diseases
  • Epidemiology

Background:

  • Hepatitis C is a significant cause of liver disease mortality in the U.S.
  • Acute hepatitis C often presents asymptomatically, leading to over 50% progression to chronic, potentially fatal infections.
  • Despite being diagnosable and curable, new hepatitis C cases are on the rise.

Purpose of the Study:

  • To analyze trends in acute and chronic hepatitis C cases reported to the CDC from 2009-2018.
  • To identify demographic groups most affected by acute and newly reported chronic hepatitis C infections.
  • To assess awareness of hepatitis C infection among affected adults.

Main Methods:

  • Analysis of National Notifiable Diseases Surveillance System data (2009-2018) for acute and chronic hepatitis C case rates by age and sex.
  • Utilized National Health and Nutrition Examination Survey data (2015-2018) to estimate the proportion of adults aware of their hepatitis C status.

Main Results:

  • Reported acute hepatitis C cases increased threefold from 2009 to 2018, with the highest rates in young adults (20-39 years).
  • In 2018, an estimated 50,300 acute hepatitis C cases occurred, with a threefold increase in annual reported cases.
  • Newly reported chronic hepatitis C cases in 2018 showed a bimodal distribution among younger (20-39) and older (50-69) adults. Only 60.6% of infected adults were aware of their diagnosis.

Conclusions:

  • Rising acute hepatitis C rates in young, reproductive-aged adults pose a risk to multiple generations.
  • New CDC recommendations emphasize universal screening for all adults and pregnant women, moving beyond historical birth year cohorts.
  • Early detection and treatment are vital to curb the increasing incidence of hepatitis C and its severe liver-related outcomes.
Abstract

More Related Videos

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

4.4K
"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

12.0K

Related Concept Videos

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.7K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
123
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
158
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
139